“…Expressing RapGAPII in A20 cells completely blocked activation of Rap1 and Rap2 by CXCL12 (Figure 1b), a chemokine that is produced in the lymphoid organs, bone marrow, liver, lungs and ovaries (Shirozu et al, 1995) and which has a key role in the dissemination of many types of tumors. RapGAPII expression selectively blocks CXCL12-induced Rap activation and does not affect CXCL12-induced activation of Akt/protein kinase B, MAP kinases or the Rac1 GTPase in B-lymphoma cell lines (McLeod et al, 2002;Durand et al, 2006). Moreover, expressing RapGAPII in A20 cells did not alter the levels of Rap1 or Rap2 (Figure 1b), did not reduce cell surface expression of CXCR4 (the receptor for CXCL12), LFA-1 or VLA-4 (Figure 1c), and did not alter the in vitro proliferation of A20 cells (Figure 1d).…”